Drug Eruption and Interactions - PHARMACEUTICAL REVIEW

248 GEFITINIB
Nephrotoxicity
(2004): Kumasaka R+, J Clin Oncol 22(12), 2504
Pain
(2006): Cersosimo RJ, Expert Opin Drug Saf 5(3), 469
Thrombophlebitis
(2004): Perras C, Issues Emerg Health Technol 55, 1
GEMCITABINE
Trade name: Gemzar (Lilly)
Indications: Pancreatic carcinoma
Category: Antimetabolite; Antineoplastic
Half-life: 42–94 minutes
Clinically important, potentially hazardous interactions
with: aldesleukin
Reactions
Skin
Acral necrosis
(2003): D’Alessandro V+, Clin Ter 154(3), 207
Allergic reactions (sic) (4%)
Cellulitis
(2003): Schwartz BM+, Gynecol Oncol 91(2), 421
Dermatitis
(2001): Fogarty G+, Lung Cancer 33(2), 299
Diaphoresis
Edema (13%)
(2003): Schwartz BM+, Gynecol Oncol 91(2), 421
(2000): Geffen DB+, Isr Med Assoc J 2, 552
(1995): Tonato M+, Anticancer Drugs 6, 27
Erysipelas
(2000): Brandes A+, Anticancer Drugs 11, 15 (confined to areas
of lymphedema)
Exanthems
(2001): Chu CY+, Acta Derm Venereol 81(6), 426
(1996): Chen YM+, J Clin Oncol 14, 1743
Hand–foot syndrome
(2005): Rini BI+, Cancer 103(3), 553 (with capecitabine)
(2003): Michaelson MD+, Cancer 97(1), 148
(2003): Scheithauer W+, Ann Oncol 14(1), 97
(2002): Dalbagni G+, J Clin Oncol 20(15), 3193
(2002): Fracasso PM+, Cancer 95(10), 2223 (with doxorubicin)
(2001): Laack E+, Ann Oncol 12(12), 1761 (with vinorelbine)
Linear IgA dermatosis
(2001): del Pozo J+, Ann Pharmacother 35(7–8), 891
Lipodermatosclerosis
(2001): Chia-Yu C+, Acta Dermato-Venereol 81(6), 426
Livedo reticularis
(2005): Gibbs MB+, JAmAcadDermatol52(6), 1009
Necrotizing vasculitis
(2003): Venat-Bouvet L+, Anticancer Drugs 14(10), 829
Petechiae (16%)
Photo-recall (